Avalo Therapeutics AVTX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accrued expenses and other liabilities?
- Avalo Therapeutics (AVTX) reported accrued expenses and other liabilities of $11.24M in Q1 2026.
- How has Avalo Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Avalo Therapeutics's accrued expenses and other liabilities increased by 145.8% year-over-year, from $4.57M to $11.24M.
- What is the long-term trend for Avalo Therapeutics's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accrued expenses and other liabilities has grown at a 2.5% compound annual growth rate (CAGR), from $11.31M to $12.8M.